Leslie A. Kenna

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 239 citations

Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006

Venkatesh Atul Bhattaram, Charles R. Bonapace, Dakshina Chilukuri et al. · Clinical Pharmacology & Therapeutics · 2007 · 118 citations

Drug Safety, Drug Interactions, Labeling Decisions—a Survey +15

Approval Summary: Nelarabine for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma

Martin H. Cohen, John R. Johnson, Tristan Massie et al. · Clinical Cancer Research · 2006 · 88 citations

A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data

Daniël M. Jonker, Leslie A. Kenna, DJ Leishman et al. · Clinical Pharmacology & Therapeutics · 2005 · 81 citations

Estimating treatment effect in the presence of non‐compliance measured with error: precision and robustness of data analysis methods

Leslie A. Kenna, Lewis B. Sheiner · Statistics in Medicine · 2004 · 10 citations